Riociguat for the Treatment of Pulmonary Arterial Hypertension

Overview of attention for article published in New England Journal of Medicine, July 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 4 news outlets
blogs: 6 blogs
policy: 3 policy sources
twitter: 25 X users
patent: 7 patents

facebook: 2 Facebook pages
wikipedia: 3 Wikipedia pages
f1000: 1 research highlight platform
guideline: 9 clinical guideline sources

Readers on

mendeley: 812 Mendeley
citeulike: 5 CiteULike

So far, Altmetric has seen 9 posts from 6 blogs.

Walk Distance versus Timed Walk - endpoints for measuring patients' function in clinical trials

On Biostatistics and Clinical Trials, 03 Nov 2023

Drug development is now moved to the patient-focused era. Patient-focused drug development (PFDD) is a systematic approach to…

Splitting p-value and estimate of treatment difference

On Biostatistics and Clinical Trials, 11 Aug 2018

When we perform the statistical test to compare the difference between two treatment groups, we usually construct a test…

A (Not So) New Drug Landscape for Pulmonary Arterial Hypertension

CardioExchange, 31 Jan 2014

John Ryan offers a primer on three newly approved drugs for pulmonary arterial hypertension.The post A (Not So) New Drug…

Riociguat for Pulmonary Hypertension: New Kid on the Block

FOAM EM RSSFOAM EM RSS, 03 Aug 2013

New Pulmonary Hypertension Drug Riociguat Proves Effective Pulmonary arterial hypertension is a rare but life-threatening…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 5 additional blog posts.